

# Jeffrey Chun Tatt Lim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10212702/publications.pdf>

Version: 2024-02-01

20  
papers

784  
citations

687363

13  
h-index

839539

18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1270  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial-mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis. <i>Journal of Clinical Pathology</i> , 2022, 75, 316-323.	2.0	2
2	Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. <i>JHEP Reports</i> , 2020, 2, 100062.	4.9	42
3	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
4	Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 369-377.	2.5	33
5	The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 709-725.	2.8	14
6	Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 295-305.	2.5	12
7	A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. <i>BMC Medical Genomics</i> , 2019, 12, 142.	1.5	20
8	Behaviour and characteristics of low-grade ductal carcinoma <i>in situ</i> of the breast: literature review and single-centre retrospective series. <i>Histopathology</i> , 2019, 74, 970-987.	2.9	6
9	Prognostic value of CD8+PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75
10	An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. <i>Pathology</i> , 2018, 50, 333-341.	0.6	65
11	Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women. <i>Journal of Clinical Pathology</i> , 2018, 71, 161-167.	2.0	23
12	An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours. <i>Annals of Diagnostic Pathology</i> , 2018, 37, 12-19.	1.3	20
13	High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1209.	4.8	114
14	Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer. <i>Oncotarget</i> , 2018, 9, 11619-11630.	1.8	11
15	Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 21-35.	2.5	102
16	Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. <i>Journal of Clinical Pathology</i> , 2017, 70, 320-326.	2.0	36
17	MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression. <i>Journal of Clinical Pathology</i> , 2016, 69, 858-865.	2.0	26
18	A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. <i>Breast Cancer Research</i> , 2016, 18, 31.	5.0	28

#	ARTICLE	IF	CITATIONS
19	<i>MED12</i> is frequently mutated in breast phyllodes tumours: a study of 112 cases. <i>Journal of Clinical Pathology</i> , 2015, 68, 685-691.	2.0	62
20	Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 19-29.	2.5	21